Morgan Griffith (R-Va.) would make it easier for patients to join clinical trials and shorten the time it takes ...
He opened by drawing a clear distinction between point solutions and embedded AI: when each function—protocol design, feasibility, monitoring, data review—uses AI in isolation, task efficiencies ...
Growing recognition of obesity as a complex, multi-system chronic disease is driving a corresponding increase in the complexity of weight management, including obesity clinical trials. As development ...
Syneos Health and Optum have announced a partnership to build what they describe as a more adaptive and connected model for ...
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, ...
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance. AstraZeneca and Oracle Health and Life Sciences have ...
CRIO’s chief innovation officer, Mike Wenger touches on the two ways sites get AI adoption wrong. Mike Wenger, chief ...
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, explains why the real advantage of faster data isn’t speed—it’s shortening ...
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option ...
Kurt Mussina, CEO, Paradigm Clinical Research, acknowledges that scale matters but pushes back on the idea that it should ...
Jennifer Byrne, CEO, Javara touches on why fixing clinical research requires sustained infrastructure investment and workforce development. Jennifer Byrne, CEO and founder, Javara, credits SCRS as a ...
Javara CEO Jennifer Byrne talks about the requirements for embedding clinical trials directly into physician practices and why solving the “last mile” of trial participation means building ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results